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Dear Editor, 
 
Attached the modified manuscript entitled: “ZnO-mesoporous glass scaffolds loaded 
with osteostatin and mesenchymal cells improve bone healing in a rabbit bone 
defect”, authored by: D. Lozano, J. Gil-Albarova, C. Heras, V.E. Gómez-Palacio, S. 
Sánchez-Salcedo, A. Gómez-Blasco , J.C. Doadrio, M. Vallet-Regí and A.J. Salinas, to be 
considered for publication in Journal of Materials Science: Materials in Medicine. 
This manuscript demonstrates that the bone healing of a critical bone defect in rabbit 
is significantly improved by implantation of scaffolds based on ZnO-containing 
mesoporous bioactive glasses as carriers of biological signals (osteostatin) and bone-
forming cells (MSCs). This system allowed us to disclose a synergistic effect of zinc and 
osteostatin in vivo, and to consider these constructs as suitable materials for bone 
substitution or repair, as a good carrier and other clinical applications. Given the 
safety, ease handling and low expense, translation of these bio-functional scaffolds 
into clinical trials is of interest to the scientific orthopedic community. 
This manuscript contains data fulfilling the Journal of Materials Science: Materials in 
Medicine standards to support the results provided. These results are original and 
unpublished, and are not under consideration for publication in any other journal.  
 
Kind regards, 
Dr.  Antonio J. Salinas 
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Abstract 
The use of 3D scaffolds based on mesoporous bioactive glasses (MBG) enhanced with therapeutic ions, 
biomolecules and cells is emerging as a strategy to improve bone healing. In this paper, the osteogenic 
capability of ZnO-enriched MBG scaffolds loaded or not with osteostatin (OST) and human mesenchymal 
stem cells (MSC) was evaluated after implantation in New Zealand rabbits. Cylindrical meso-macroporous 
scaffolds with composition (mol %) 82.2SiO2–10.3CaO–3.3P2O5–4.2ZnO (4ZN) were obtained by rapid 
prototyping and then, coated with gelatin for easy handling and potentiating the release of inorganic ions 
and OST. Bone defects (7.5 mm diameter, 12 mm depth) were drilled in the distal femoral epiphysis and 
filled with 4ZN, 4ZN+MSC, 4ZN+OST or 4ZN+MSC+OST materials to evaluate and compare their 
osteogenic features. Rabbits were sacrificed at 3 months extracting the distal third of bone specimens for 
necropsy, histological and microtomography (µCT) evaluations. Systems investigated exhibited bone 
regeneration capability. Thus, trabecular bone volume density (BV/TV) values obtained from µCT showed 
that the good bone healing capability of 4ZN was significantly improved by the scaffolds coated with OST 
and MSC. Our findings in vivo suggest the interest of these MBG complete systems to improve bone repair 
in the clinical practice. 
Keywords: Mesoporous bioactive glasses; ZnO; osteostatin; in vivo evaluation; bone regeneration. 
1 Introduction 
In a bone damage scenario, bone repair is a spontaneous process which takes place in physiological 
circumstances. However, there are some clinical situations in which this process may not be sufficient. In 
those cases, bone repair can be achieved by bone engineering [1-3]. During the last years, mesoporous 
bioactive glasses (MBGs) based on SiO2–CaO–P2O5 have arisen as exceptional material to develop 
scaffolds which constitute a perfect tool for this purpose. The description that certain glasses, in the SiO2–
CaO–P2O5–Na2O system, could chemically bond with bone was first reported in 1971 [4]. These glasses 
often denoted as bioglasses, obtained by quenching of a melt, attained the FDA clearance in 1985 to be 
used for replacement of the middle ear ossicles and later on for other maxillofacial and dental applications 
including the treatment of periodontal disease. In 2000, bioglasses were approved for orthopaedics bone 
grafts in non-load bearing sites, which is the application that will be explored in this paper. Moreover, in 
2004 they were approved for the treatment of dentinal hypersensitivity. In the last decades, many researches 
were conducted in this area following a double way. On the one hand, new applications of bioactive glasses 
were sought outside the skeletal system like the peripheral nerve repair, wound healing and many others 
including the cancer treatment. On the other, it was seeking to improve their performance in the body with 
new methods of synthesis that lead to porous materials, sol-gel glasses [5] and to obtain them with huge 
ordered mesoporosity using surfactants as templates [6]. These new methods of synthesis yield to glasses 
more reactive than traditional ones that exhibited the extra capability to be loaded with osteogenic 
substances that can be released in a controlled way. The emergence of bone tissue engineering confirmed 
Manuscript Click here to download Manuscript Lozano D et al.
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 2 
that biomaterials by themselves, in this case the glasses were not enough for an accurate treatment of bone 
defects. 
In this sense, MBGs present bone regenerative properties and high order mesoporous structures which 
are able to load and release bone tissue promoting agents [1,2,7,8]. MBGs also presents huge surface area 
and pore volume what causes quicker in vitro responses than other bioactive materials [7,9]. Besides, MBG 
degradation increases intracellular ion concentration of their basics constituents, i. e., Si (IV), Ca2+ and P 
(V) which could lead to the activation of bone regeneration intracellular signaling pathways [10,11]. 
Moreover, MBGs bone regeneration features can be enhanced by the addition of certain inorganic ions with 
biological activity such as Cu2+, Mg2+, Ce3+, Co2+, Ga3+, Sr2+ or Zn2+. In this regard, Zn2+ ions, showed good 
properties, due to their specific capacity to increase osteogenesis [12], angiogenesis [1,12] and their 
antimicrobial properties [12,13]. 
One of the most promising strategies under investigation to improve bone healing implicates the use 
of the scaffolds in combination with human mesenchymal stem cells (MSC) and osteogenic and angiogenic 
factors, such as parathyroid hormone (PTH)-related protein, PTHrP. This protein contains an N-terminal 
1-37 fragment that is similar to PTH and a C-terminal region (not homologous to PTH), containing 107-
111 sequence (osteostatin, OST) [14]. This family of peptides has been shown to modulate bone 
metabolism. For instance, N-terminal PTHrP analogues have shown to enhance bone metabolic pathways 
in humans and rodents upon systemic intermittent administration [15-17]. Besides, C-terminal fragment of 
PTHrP, known as OST, have shown to display anti-resorptive activity [18], also exhibiting osteogenic 
properties both in vitro and in vivo [19–24]. In addition, it was recently shown that OST coatings on several 
bioceramics and other biomaterials accelerates the healing of critical and non-critical long-bone defects in 
healthy and osteoporotic adult rabbits and rats [25–28]. Besides, our group has recently reported a 
synergistic effect of Zn2+ ions and OST, enhancing cell growth and osteogenic differentiation of pre-
osteoblastic MC3T3-E1 cells in dense MBG disks [29], and of human MSCs in 3D meso-macroporous 
scaffolds analogous to those used in the present study [30]. These recent findings point to OST in 
conjunction with human MSC an attractive tool to be considered in bone tissue engineering approaches.  
The aim of the present study was to design and evaluate an improved biomaterial, based on the above-
mentioned scaffolds. Pristine meso-macroporous 82.2%SiO2–10.3%CaO–3.3%P2O5–4.2%ZnO (mol %) 
(4ZN) scaffolds and after be loaded with OST (4ZN+OST),  human MSC (4ZN+MSC) or both 
(4ZN+MSC+OST), were implanted for 3 months in defects (7.5 mm diameter, 12 mm depth) drilled in the 
distal femoral epiphysis of New Zealand rabbits. 
2 Materials and Methods  
2.1 Synthesis and characterization of the scaffolds 
Production and characterization of the scaffolds with composition 82.2%SiO2–10.3%CaO–
3.3%P2O5–4.2%ZnO (mol %) were described in detail in [30]. There, half-size analogous scaffolds 
(identical diameter, half height) were reported, investigating the loading and release of OST and the 
interaction with human MSC. MBGs were synthesized by the evaporation induced self-assembly (EISA) 
technique, and MBG scaffolds as 3D structures were obtained by rapid prototyping 3D printer rapid 
prototyping equipment 3D Bioplotter™ (EnvisionTEC, Gladbeck, Germany) printer. The dimensions of 
the obtained cylindrical scaffolds were 7 mm diameter x 10 mm height. After its calcination at 700 °C, 
scaffolds were coated by immersion in 2.4 % gelatin (GE) cross-linked with glutaraldehyde (GA) (0.05 
w/v-%), giving rise to 4ZN scaffolds. The 4ZN scaffolds were exhaustively characterized in reference [26]. 
Briefly, interconnected macroporosity of MBG scaffolds and its chemical composition was analyzed in a 
JEOL JSM-6400 scanning electron microscope (SEM) (Tokyo, Japan) operating at 20 kV and equipped 
with an Oxford Instruments INCA Energy Dispersive X-ray (EDX) spectrometer. Mesoporous channel 
arrangement was evaluated by transmission electron microscopy (TEM) of crushed scaffolds carried out in 
a JEOL2100 electron microscope operating at 200 kV (Tokyo, Japan). To assess the composition of the 
scaffolds coated with GA cross-linked GE, Fourier transform infrared (FTIR) spectroscopy was performed 
in a Thermo Scientific Nicolet iS10 apparatus equipped with a SMART Golden Gate® attenuated total 
reflection ATR (Waltham, MA, USA). Thermogravimetric analyses (TGA) were carried out with a Perkin-
Elmer Pyris Diamond TG/DTA instrument, between 30 and 900 °C in air at a flow rate of 100 mL/min and 
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 3 
a heating rate of 10 °C/min. The studied scaffolds were included into the culture medium (complete α-
MEM, Minimum Essential Medium) for 10 days. The scaffolds were located in a 12 transwell plate in 
contact with the culture medium and 100 rpm shaking conditions. Culture medium was extracted every day 
to measure the zinc, calcium, phosphorous ions content in the solution by inductively coupled 
plasma/optical emission spectrometry (ICP/OES) using an OPTIMA 3300 DV Perkin Elmer device 
(Waltham, MA, USA).  
2.2 Osteostatin loading and human mesenchymal cells seeding  
4ZN scaffolds were incubated in 24-well plates with 1 mL of phosphate-buffered saline (PBS) at pH= 
7.4 containing 100 nM OST (4ZN+OST). Materials were left overnight under stirring (400 rpm) at 4 °C. 
OST adsorption after 24 h was calculated based on the amount of peptide removed from the medium; 
whereas OST release was measured by soaking the peptide-loaded scaffolds in PBS also under stirring at 
4°C [30]. We found that the mean retention of osteostatin by 4ZN scaffolds after 24 h of loading was 50 
%, equivalent to 0.70 μg osteostatin/g scaffold. These loaded materials released (mean) 50% of loaded 
peptide to the surrounding medium within 1 h; 85% at 24 h; and virtually 100 % at 96 h (data not shown). 
Human MSC (Lonza, Walkersville, MD, USA) were withdrawn from the posterior iliac crest of the pelvic 
bone of normal volunteers. Human bone marrow cells are frozen in passage two and we used by passage 
five. Cell seeding in OST-loaded scaffolds was performed as described [30]. In short, scaffolds were placed 
into 24-well plates before human MSC seeding [31], purchased from Lonza (Walkersville, MD, USA). A 
suspension at 4•105 cells/scaffold was seeded on the top of each scaffold. After 30 min of seeding, each 
well was filled, until 2 mL, with MSC basal medium from Lonza (MSCBMTM), containing 10% fetal 
bovine serum (FBS), 1mM L-Glutamine and 1% penicillin–streptomycin at 37 °C in a humidified 
atmosphere of 5% CO2, and incubated for 2 days. Medium was replaced every day. 
2.3 Surgical procedure 
The study employed twelve female New Zealand rabbits, 6 months old and weighing on average 3.9 
± 0.3 kg. By means of a motorized drill, bone defects (7.5 mm diameter x 12 mm depth) were carved in the 
lateral aspect of both distal femoral epiphyses of all rabbits with continuous irrigation using physiological 
saline to prevent bone necrosis. Bone defects were then randomly filled during the surgical procedure with 
the scaffolds previously described. The animals continued the postoperative period in individual cages, 
under standard conditions (room temperature 20.0 ± 0.5 °C, relative humidity 55 ± 5% and illumination 
with a 12 h/12 h light/dark photoperiod), fed with full rabbit special fodder (Nantas®), given water ad 
libitum, and without movement restrictions. Surgery was accomplished under aseptic conditions by general 
anesthesia induced by subcutaneous injection of ketamine (25 mg/Kg) and medetomidine (0.5 mg/Kg), and 
intraspinal anesthesia. Intraoperative analgesia and anesthesia was maintained by means of Fentanyl and 
Lidocaine in saline serum up to a volume of 1 mL in the spinal canal. Ringer-Lactate intravenous solution 
was administered at a rate of 8 mL/Kg/h during the surgery. 
Postoperative analgesia was maintained during 5 days by subcutaneous injection of Meloxicam 0.2 
mg/Kg daily, and antibiotic prophylaxis was performed by means of two injections of Cefazoline (50 
mg/Kg). Final euthanasia was carried out after 3 months of follow-up the animals and then 0.5 g of 
intravenous sodium thiopental were administered. The postoperative incidents during the experimental 
period are detailed in the supplementary material. Bone specimens obtained in the present study were 
processed for µCT and histological study. Some specimens were used in both studies, but the µCT was 
always previously performed.  
The features of the created bone defects agreed with critical bone defects following the established 
requirements [32-36]. A gold standard group (control group) was not performed. Given the existence of 
numerous clinical and experimental evidences (of our research group and others) [37,38] that the bone 
autograft is the gold standard in the treatment of bone defects, Ethical Commission for Animal 
Experimentation encouraged us to reduce the number of experimental animals to the minimum necessary, 
not including any control group. This recommendation avoids the unnecessary suffering of experimental 
animals, which is a common practice in experimental surgery. All procedures were carried out under Project 
License PI33/14 approved by the in-house Ethic Commission for Animal Experiments from the University 
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 4 
of Zaragoza (Spain). The care and use of animals were performed accordingly with the Spanish law (RD 
53/2013) and international standards on animal welfare as defined by European Directive (2010/63/EU). 
2.4 Radiographic and histological evaluation 
After surgery, a radioscopic routine examination of the lateral vision of the operated femur was 
achieved to assess the implant placement. After sacrifice, the distal third of the bone specimens was 
extracted for histological study. Bones fixed with formaldehyde were dehydrated in alcohol graded series 
from 50% to 100%, and embedded in methyl methacrylate (Merck Schuchardt OHG, Germany). Sagittal 
sections obtained with a cutting–grinding system (EXAKT Apparatebeau GMBH, Norderstedt, Germany) 
were stained with hematoxylin and eosin (H&E) and Masson–Goldner trichrome for histological 
evaluation. Thickness of the grinding sections was 4-9 µm for H&E staining, and 5-19 µm for Masson–
Goldner trichrome staining. Histological sections were examined with a Zeiss AxiokoP 40 microscope 
(Oberkochen, Germany) and microphotographs were obtained with a Zeiss AxioCam MRc5 camera. Light 
microscopy histological images with two different magnifications were shown. Images of panel a and b are 
of the same group, but those of b are not always close-up of a panel. For the sake of clarity, B panels 
showed representative images of the majority of the osteogenic effects observed in each group. 
2.5 X-ray microtomography 
The sample size requirements for the µCT study did not allow the introduction of the complete femur 
of rabbits. The distal third of the bone specimen from each rabbit were cut with a diamond disk and then 
scanned by high-resolution X-ray microtomography (µCT) in a BioScan nanoSPECT-CT (Dallas, TX, 
USA). The X-rays source is a continuously operating miniature micro focus X-ray tube with air filtration 
only. The detector is a high-resolution radiation-imaging device featuring a 1024 by 2048 pixels photodiode 
array with 48 μm pixel spacing. The scintillator screen is made of Gd2OI2S. The study was carried out with 
65 kV of Tube Voltage, 1300 ms of Exposure time: 1300 ms, 360 projections and 0.5 pitches. The three-
dimensional microstructural properties of the bone region of interest (Supplementary Fig. 1) were assessed 
by using the image software Vivoquant 2.0® (Invicro). The % of bone volume per total volume (BV/TV) 
around each scaffold (at 350 µm and 700 µm distance from the scaffold) was calculated. 
 
2.6 Statistical Analysis 
Results were expressed as mean ± standard error of the mean (SEM). Statistical analysis was 
performed through nonparametric Kruskal-Wallis test and post hoc Dunn’s test. A value of p < 0.05 was 
considered significant. 
 
3 Results 
The synthesis and characterization of this batch of scaffolds was previously described in detail by our 
research group [30]. There, three compositions were investigated, first ZnO-free and the other two 
containing respectively 4% and 5% ZnO. MBG loaded and unloaded with OST and its interactions with 
human MSC were also described. These in vitro results showed the added value of scaffolds to be 
containing simultaneously ZnO and OST because of the synergistic effect in the growth and osteogenic 
differentiation of MSC, being significantly more effective in 4% ZnO scaffolds. These results prompted us 
to investigate their behavior in an animal model. Scaffolds size were larger now (same diameter, double 
length) to fit the dimensions of the produced critical bone defect. As previously explained, four series of 
materials (pristine 4ZN, 4ZN+MSC, 4ZN+OST, and 4ZN+MSC+OST) were assessed in an animal model.  
 
3.1 Implantation of 4ZN-based scaffolds in a bone defect in the rabbit femur 
A critical bone defect (7.5 mm Ø x 12 mm depth) was created, in the lateral distal femoral epiphyses 
in all rabbits. Defect images, surgical implantation of 4ZN scaffold and its blood imbibition from the 
recipient bone bed are shown in Fig. 1a. To asses an implant placement, after surgical implantation, a 
radioscopic routine examination of the lateral vision of the operated femur was performed (Fig. 1a). 
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 5 
3.2 Necropsy study 
Animals were sacrificed and femoral specimens were extracted and analyzed macroscopically (Fig. 
2) before being processed for µCT and histological studies. 
In the specimens treated with 4ZN scaffolds, the defect was filled with bone. Occasionally, the circular 
area of implantation, covered with newly formed bone, could be delimited. Alterations of normal femoral 
morphology were observed at the time of surgical implantation in two specimens due to the femoral condyle 
healed fracture. No scaffolds prominences or macroscopic remains were detected. Similarly, the treated 
bone defects appeared coated with bone in the specimens treated with 4ZN+MSC, perceiving macroscopic 
alterations. One specimen showed a healed fracture of the femoral condyle, detected from the surgical 
intervention, which altered the final femoral morphology. No morphological alterations were observed in 
the other specimens, although in one of them, a hemi-spherical bone prominence was observed delimiting 
the circular area of implantation. 
In the same way, bone defects treated with 4ZN+OST were covered with bone. Occasionally, a 
brownish color underlying the newly formed bone delimiting the implantation area, was detected. In one 
specimen there was an alteration, detected in the moment of the intervention, of the femoral morphology, 
secondary to the healed fracture of the femoral condyle. 
As in the previous groups, bone defects treated with 4ZN+MSC+OST were covered with bone in all 
the specimens. The hemi-spherical bony prominence with brownish color delimiting the circular area of 
implantation was much more relevant than in the other groups. 
3.3 Histological study 
Implants were recognizable inside all bone specimens in methyl methacrylate blocks, but not always 
in the histological sections. It could be because of the procedure of polishing and sanding the histological 
sections of the EXAKT method, made before staining the cuts. Moreover, no sign of inflammation or 
adverse tissue reaction were observed around implants. 
Fig. 3 shows the histology results of the specimens treated with 4ZN scaffolds. In the histological 
sections, the implants and their limits were not clearly detected. Non-reabsorbed portions of the scaffolds 
were recognizable with a delimiting osteofibrous frame (Fig. 3a). In some compact bone formations, 
elements of irregular morphology and crystalline appearance were observed; suggesting bone neoformation 
in the remains of the implanted material (Fig. 3b). The original structure of the implanted scaffolds was not 
clearly identified because of centripetal degradation. 
Fig. 4 shows the histology results of the specimens treated with 4ZN+MSC. The histological sections 
showed the implantation limits, being recognizable portions of the macroscopic structure of the ceramic 
cylinder surrounded by an osteofibrous cup. The presence of a relatively thick fibrous frame induced by 
4ZN (Fig. 5a) was reduced by the presence of MSC (Fig. 4a). 
Moreover, spicules of compact bone were observed around the implant area. These spicules, and the 
compact bone structure observed in some points, included a fragmented crystalline type material. At other 
points, this crystalline material seemed to be integrated into compact bone. In others, it appeared 
fragmented without having any relation to the bone or delimited by dense masses of cells. These findings 
suggest greater bioactivity and osseointegration (Fig. 4b). As observed in the previous group, implants were 
recognizable inside the bone specimens in methyl methacrylate blocks with modifications of its peripheral 
morphology. 
In specimens treated with 4ZN+OST, implants and their limits were not clearly appreciated, except in 
one of the specimens investigated. An osteofibrous frame could be observed delimiting the place of 
implantation, with remaining areas of crystalline material inside compact bone (Figs. 5a, b). Therefore, 
OST loading in 4ZN scaffolds promoted the proliferation of osteogenic precursor cells and connective 
tissue formation. The fibrous frame was reduced in these specimens compared with pristine 4ZN scaffolds 
(Fig. 5a). In specimens treated with 4ZN+MSC+OST, remains of the degraded implants were clearly 
identified with less sharpness and surrounded by a thin osteofibrous frame (Fig. 6a). The combination of 
OST and MSC in 4ZN induced a neoformed bone trabeculae in intimate contact suggesting osseointegration 
(Fig. 6b).  
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3.4 µCT study  
Bone repair and bone tissue response to the implanted scaffolds, in combination or not with MSC 
and/or OST, were also examined by µCT in the scaffold-tissue interface and in the peripheral area of the 
implant (Fig 7, top).   
For the specimens treated with 4ZN, degraded implants were observed with variable loss of their 
initial morphology, surrounded by less radiological density area, probably due to peripheral resorption. In 
some portions of its surface, the appearance of bony trabeculae was detected contouring the implant as a 
bone frame. In the specimens treated with 4ZN+MSC, remains of the degraded implants were present in a 
more homogeneous form than observed in the previous group. Moreover, it was also detected a lower 
peripheral radiological density area which seems to correspond to the centripetal resorption of the implants. 
As in the previous group, portions of bone framing of the implants surrounding the centripetal degradation 
zone were observed. In a similar way than detected in other groups, specimens treated with 4ZN+OST 
showed greater centripetal degradation, although not having homogeneous implants. It was also appreciable 
a peripheral halo of lower radiological density, delimited by a bony framework. In the specimens treated 
with 4ZN+MSC+OST scaffolds, the degradation was greater than in previous groups, with also centripetal 
predominance although not following a homogeneous pattern. Radio dense bands that could correspond to 
newly formed bone were observed with a lower peripheral density zone around the remains of the implants 
and also delimited by a bony frame. 
The osteoconductive and osteoinductive effects of OST and MSC loaded into 4ZN scaffolds, observed 
in µCT images and in histological analysis, were confirmed by the quantification of the % bone volume per 
total volume (BV/TV) in the nine bone specimens investigated. We found that OST loaded scaffolds or 
MSC decorated scaffolds significantly increased % BV/TV, compared to pristine 4ZN. This positive effect 
was more evident when the scaffolds were combined with OST and MSC together (Fig. 7 bottom). In terms 
of percentage, a greater BV/TV (35 %) were measured in scaffolds combined with OST and MSC, than in 
MSC decorated scaffolds (26%) or OST loaded scaffolds (28 %). Finally, 4ZN exhibited the lower BV/TV 
value (15 %).  
4 Discussion 
It must be taken into account that an ideal bone substitute should be osteogenic, biocompatible, bio 
absorbable, capable of providing structural support and release biologically active substances. Moreover, 
it must be easy handling in clinic with an adequate cost-benefit ratio. The scaffolds designed for this study 
showed the composition, dimensions and porosity desired to treat the investigated bone defect. Due to this, 
designed scaffold were optimal for bone tissue engineering application. Moreover, they were readily loaded 
with OST and/or MSC. 
Necropsy, histological and 3 months of implantation µCT results, suggested that all the scaffolds 
assessed allow bone growth over their surface, by a mesenchymal cells recruitment process from the 
surrounding bone and its subsequent transformation in bone forming cells as consequence of local 
bioactivity [2,7,37,38]. According to Shors [39] bone formation over a bioactive implant in ideal conditions, 
should be predominantly of membranous type. In our study, bone and fibrous tissue were observed over all 
implants but without chondral cells, as evidence of an ideal membranous type of bone growth. Our 
observations supported the evidence of bone viability where implants were fixed, one of the three 
requirements of Shors [39] ‘‘triad of osteoconduction’’: stability, viability and proximity. The healing of 
critical bone defects demonstrated the viability of the epiphyseal and metaphyseal bone to facilitate the 
osseointegration process of the tested scaffolds. As previously mentioned, EXAKT band and polishing saw 
system have specific characteristics that can vary the observation and evaluation of the stains compared to 
the characteristics observed in deparaffinized sections. The inflammatory process is a combination of 
clinical, tissue, cellular and biochemical phenomena. In experimental surgery we can assess the clinical 
aspects of the inflammatory process during clinical postoperative follow-up, necropsy and postmortem 
histological study, which supported an adequate in vivo bioactivity [37,38]. No inflammatory abnormalities 
were observed other than the usual ones of a satisfactory postoperative period, nor during the autopsy.  
Evidence of degradation and absorption of implanted cylinders was clearly observed following the 
conditions of Bauer and Muschler [40] for bone remodeling of a synthetic bone graft substitute, with 
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progressive growth of bone and fibrous tissue to heal the bone defect. This positive effect on bone growth 
and remodeling was previously observed with similar bioglass scaffolds that contain polypeptides in vivo 
[2,41, 42], and by our group [25-27,37,38], with others materials in critical and non-critical bone defects, 
suggesting a process of mesenchymal cells recruitment of surrounding tissues and subsequent 
transformation in bone-forming cells. The size of critical bone defects created in this study according to the 
standard requirements [32–36] may explain the occasional posterior bed bone marginal fractures observed 
during implantation, although without instability of the implanted scaffold. The healing of these 
intraoperative fractures explains the morphological alterations observed in some specimens during the 
necropsy. 
Several scaffold preparation techniques can be found in the literature. Some of them have been 
adapted from other research areas or have been achieved through modification of traditional techniques 
[43–45]. Moldable and 3D printable composite scaffolds are an interesting type of materials that can find 
suitable application as fillers in bone reconstructive surgery and in the treatment of particular clinical and 
experimental situations [2,27,28,43,45,46]. The design of scaffolds for bone regeneration based on 
biodegradable polymers must consider the polymer and the resulting scaffold mechanical strength, and 
even its shape, according the place of implantation and clinical or surgical requirements. Bones must 
withstand high pressures and may be necessary the scaffold to present high mechanical strength, including 
both compressive and tensile strength. These properties are necessary until the regenerated tissue owns 
sufficient mechanical strength itself [36]. The presence of biological signals as growth factors, OST or zinc 
inside of the scaffold, should improves bone regeneration, being an important aid when, in certain clinical 
or experimental situations, natural bone repair is not enough [1,2,15,25,26,45-47]. Growth factor instability 
can be overcome through loading it into a carrier that protects the protein and promotes its controlled release 
hence prolongs its activity whenever administered into the body [43,45]. In this regard, OST displays some 
important advantages compared with other osteogenic proteins, as BMPs for example [2]. This peptide has 
shown to display anti-resorptive activity but also osteogenic properties both in vitro and in vivo, while 
BMPs exerts osteogenic features but can be adipogenic at high doses. These positive effects of OST are 
specific of bone cells and keratinocytes, while BMP-2 effects are pleiotropic, acting on many tissues and 
activating the immune system [2]. OST is a small pentapeptide easy to immobilize in different biomaterials, 
active at low concentrations (<nM) and very important for local applications. Conversely, BMP-2 has a 
larger molecular weight, making more difficult to immobilize in materials, and higher concentrations (>nM) 
are required to induce osteogenic effects [2].  
In a previous study, we demonstrated in vitro for the first time, a synergistic effect of zinc and OST 
to enhance MSC cell growth and osteogenic differentiation, suggesting its potential use in bone tissue 
engineering applications [30]. Here, the use of MGB scaffolds doped with 4.2% ZnO, loaded with OST 
and decorated with MSC significantly improved bone regeneration, reducing the fibrous cup induced by 
4ZN scaffolds, providing a novel and interesting insight in the field of bone regeneration. These results are 
in concordance with previous studies of our group where OST loading on different bioceramics and other 
biomaterials improves the healing of critical and non-critical long-bone defects in healthy and osteoporotic 
adult rabbits and rats [25-28,48]. Thus, OST, in combination or not with MSC, increased in vitro osteogenic 
capacity of Zn2+ ions enriched materials, as we demonstrated by increasing % BV/TV, suggesting the 
potential of this method in bone tissue engineering applications [2]. Moreover, the release of Zn2+ ions from 
the scaffold is thought to stimulate the osteoblastic bone building process and reduce the osteoclastic 
resorption process [29,44,47,49-51]. 
The histological findings and the µCT images point towards a centripetal degradation of the implants 
and bone repair with healing of the bone defect predominantly of membranous type in the same direction. 
In our study, 4ZN scaffolds showed evidence of osseointegration with a progressive loss of its initial 
morphology, even though all the studied groups were inhomogeneous, without complete resorption after 
three months of implantation. These qualitative findings are supported by the measured % BV/TV in the 
four different scaffold combinations. Similar findings have been described in comparative experimental 
models of bone defect, although those were not critical and with different follow-up time [25,26].  
As we previously mentioned, certain bone defects that have scarce or null capacity of regeneration 
need to be treated with bone grafts that favored the repair process. For this goal, bone autografts are the 
gold standard, but these grafts have limitations in obtaining osseous tissue needed and the morbidity in the 
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donor area. Thus, there is an urgent necessity to design biomaterials capable of substitute autografts without 
its limitations. Several research groups face this problem by using bone tissue engineering principles based 
on three-dimensional scaffolds loaded with biomolecules and decorated with mesenchymal cells. 
Nevertheless, our present study has been the first to investigate bioactive mesoporous glasses, improved by 
adding an osteogenic and bactericidal ion such as zinc and an osteogenic and anti-resorptive pentapeptide 
(osteostatin), in addition to human-mesenchymal bone marrow cells. In addition, further in vivo studies at 
longer experimental times and in superior animals as sheep or pig, will be necessary before the clinical 
trials that yield to the clinical use of these materials. However, our results suggest that the loading of Zn-
containing MBG scaffolds with MSC and OST significantly improves the bone healing because of inducing 
neo-formed bone trabeculae in intimate contact with a higher rate of implants degradation, increasing % 
BV/TV and reducing the fibrous frame induced by the unloaded scaffolds. 
5 Conclusions 
The osteogenic capability of 3D meso-macroporous biomaterials based on ZnO-enriched mesoporous 
bioactive glass scaffolds combined with osteostatin and human mesenchymal stem cells were evaluated 
after 3 months of implantation in New Zealand rabbits. The present study showed for the first time that the 
healing process in a critical bone defect was clearly improved by the implantation of these scaffolds 
investigated as carriers of biological signals (osteostatin) and bone-forming cells, compared with non-
loaded ZnO-enriched scaffold. Therefore, biomaterials here investigated promote advantageous local 
biological conditions leading to very remarkable results in bone regeneration field. Given the safety, ease 
of handling and low expense, translation of this bio-functional biomaterial into clinical bone reconstructive 
surgery of personalized implants is of interest to the scientific orthopedic community. 
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Figure Legends 
 
Fig. 1 a Digital image of the surgical implantation of 4ZN scaffold and its blood imbibitions of the recipient 
bone bed. b X-ray images of bone defect without and with a scaffold (sc) implanted in femoral epiphysis. 
 
Fig. 2 Macroscopic appearance of bone specimens implanted 3 months with different scaffolds after 
necropsy. Arrows indicate the implants position. 
 
Fig. 3 Light microscopy from hematoxylin/eosin (a and b, left panels) and Masson–Goldner Trichrome (a 
and b, right panels) sagittal stained sections of the area surrounding 4ZN scaffolds (sc), containing newly 
formed bone at 3 months after production of a bone defect. Initial defect area is depicted with a yellow 
circle. Compact bone (CB) formation enveloping some not reabsorbed portions of the cylinder was 
observed (arrows). FC= fibrous cap.  
 
Fig. 4 Light microscopy from hematoxylin/eosin (a and b, left panels) and Masson–Goldner Trichrome (a 
and b, right panels) sagittal stained sections of the area surrounding 4ZN+MSC scaffolds (sc) containing 
newly formed bone at 3 months after production of a bone defect. Initial defect area is depicted with a 
yellow circle. In detail, crystalline material integrated into compact bone (CB) and fragmented without 
relation to the bone or delimited by dense masses of round cells (arrows). 
 
Fig. 5 Light microscopy from hematoxylin/eosin (a and b, left panels) and Masson–Goldner Trichrome (a 
and b, right panels) sagittal stained sections of the area surrounding 4ZN+OST scaffolds (sc) containing 
newly formed bone at 3 months after production of a bone defect. Initial defect area is depicted with a 
yellow circle. In detail, crystalline material integrated into compact bone (CB) and fragmented without 
relation to the bone or delimited by dense masses of round cells (arrows). Bone trabeculae = BT.  
 
Fig. 6 Light microscopy from hematoxylin/eosin (a and b, left panels) and Masson–Goldner Trichrome (a 
and b, right panels) sagittal stained sections of the area surrounding 4ZN+MSC+OST scaffolds (sc) 
containing newly formed bone at 3 months after production of a bone defect. Initial defect area is depicted 
with a yellow circle. In detail, bone trabeculae (BT) in intimate contact with the degraded material 
suggesting osteointegration (arrows). 
 
Fig. 7 Representative µCT projection images of the area surrounding the different scaffolds (sc), containing 
newly formed bone 3 months after production of a bone defect. At the bottom of the figure trabecular bone 
volume per total volume (BV/TV) measured by µCT around the different type of scaffolds in the bone 
defect. Results are mean ± SE.* p < 0.05 vs. 4ZN scaffold; # p < 0.05 vs. 4ZN+ MSC and 4ZN+ OST 
scaffolds. 
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